Critical Appraisal Practicum. Fabio Di Bello Medical Implementation Manager
|
|
- Doreen Nichols
- 5 years ago
- Views:
Transcription
1 Critical Appraisal Practicum Fabio Di Bello Medical Implementation Manager
2 What we ll talk about today: DynaMed process for appraising randomized trials and writing evidence summaries about treatment efficacy Background Levels of Evidence (LOE) Quality Criteria Summary Structure Example How the critical appraisal process is reflected in the study summary Hands-on practice and Discussion
3 Levels of Evidence LOE: a 3-tiered system for categorizing the validity of evidence based on the Strength of Recommendation Taxonomy (SORT) Level 1 (likely reliable) Evidence methodologically rigorous randomized trials and systematic reviews that address patient-oriented (clinical) outcomes judged to be free of significant sources of bias Level 2 (mid-level) Evidence Studies addressing patient-oriented outcomes, using a method of scientific comparison, but including 1 major potential bias Level 3 (lacking direct) Evidence Studies (including RCTs) with surrogate outcomes only Reports based on uncontrolled analysis of patient-oriented outcomes (e.g. case series)
4 Critical Appraisal Systematic evaluation of the methodologic quality of a study to identify any sources of potential bias that may limit the validity of the findings
5 Critical Appraisal Systematic evaluation of the methodologic quality of a study to identify any sources of potential bias that may limit the validity of the findings o DynaMed criteria for level 1 (likely reliable) evidence for interventional conclusion (conclusions that an intervention does or does not change an outcome) 1. Full-text report available in English (or language well understood by participating editor) 2. Clinical outcome (also called patient-oriented outcomes) 3. Population, intervention, comparison, and outcome in the study is representative of expected clinical practice 4. Random allocation method (i.e. not assigned by date of birth, day of presentation, every other ) 5. Blinding of all persons (patient, treating clinician, outcome assessor) if possible 6. Follow-up (endpoint assessment) of at least 80% of study entrants AND adequate such that losses to follow-up could not materially change the results 7. Accounting for dropouts (even if not included in analysis) 8. Adequate precision of effect estimate based on 1. Confidence intervals do not include both presence of no effect (relative risk ) and presence of substantial relative effect (such as relative risk <0.75 or >1.25) 2. Adequate power (based on sample size and observed control event rate) to detect clinically important differences 9. Consistency of findings across measures of similar outcomes 10. In cases of randomized parallel-group trials Allocation concealment Intention-to-treat analysis comparing groups according to randomization 11. No other factors contributing to substantial bias, such as Differences in management between groups other than the intervention being studied Differential loss to follow-up Posthoc analysis Subgroup analysis Baseline differences between groups Unclear how missing data are accounted for if possible
6 Critical Appraisal Systematic evaluation of the methodologic quality of a study to identify any sources of potential bias that may limit the validity of the findings o DynaMed criteria for level 1 (likely reliable) evidence for interventional conclusion (conclusions that an intervention does or does not change an outcome) 1. Full-text report available in English (or language well understood by participating editor) 2. Clinical outcome (also called patient-oriented outcomes) 3. Population, intervention, comparison, and outcome in the study is representative of expected clinical practice 4. Random allocation method (i.e. not assigned by date of birth, day of presentation, every other ) 5. Blinding of all persons Threats (patient, treating clinician, to outcome Validity assessor) if possible 6. Follow-up (endpoint assessment) of at least 80% of study entrants AND adequate such that losses to follow-up could not materially change the results 7. Accounting for dropouts (even if not included in analysis) Trial design weaknesses 8. Adequate precision of effect estimate based on 1. Confidence intervals do not include both presence of no effect (relative risk ) and presence of substantial relative effect (such Procedural as relative risk <0.75 concerns or >1.25) 2. Adequate power (based on sample size and observed control event rate) to detect clinically important differences Statistical analysis issues 9. Consistency of findings across measures of similar outcomes 10. In cases of randomized parallel-group trials Allocation concealment Intention-to-treat analysis comparing groups according to randomization 11. No other factors contributing to substantial bias, such as Differences in management between groups other than the intervention being studied Differential loss to follow-up Posthoc analysis Subgroup analysis Baseline differences between groups Unclear how missing data are accounted for if possible
7 Critical Appraisal: Threats to Validity Trial Design Weaknesses Lack of allocation concealment Lack of blinding of patients and study personnel (when possible) Sample size < 30 patients per group Procedural Concerns Baseline differences between groups High rates of dropout or loss to follow-up (> 20%)
8 Critical Appraisal: Threats to Validity Statistical Analysis Issues Lack of intention-to-treat analysis Post hoc analysis Confidence Intervals that indicate imprecise effect estimates Non-significant results with wide CIs Skewed CIs including both clinically important and unimportant results Statistically significant results without clear clinical importance
9 The DynaMed Summary LOE is reflected in the phrasing of the summary conclusion. LOE1 vs. LOE2: sure, assertive statement vs. provisional statement LOE1: LOE2: intervention X reduces pain intervention X may reduce pain The DynaMed Conclusion may not agree with the author s conclusion may highlight outcomes other than those considered most important by the authors
10 The DynaMed Summary When we downgrade from LOE1, we have to explain why presented on the second line of the summary (basis statement) Only a single downgrade reason is needed additional concerns can be addressed in the body of the summary. But multiple flaws does not mean further downgrading! The downgrade reason identifies the potential bias that is most relevant to the conclusion being drawn. Frequently the downgrade requires additional explanation in the body of the summary.
11 Indian J Pediatr Jul;78(7): Epub 2011 Feb 2. Unsynchronized Nasal Intermittent Positive Pressure Ventilation to prevent extubation failure in neonates: a randomized controlled trial. Abstract OBJECTIVE: To evaluate the role of Unsynchronized Nasal Intermittent Positive Pressure Ventilation (NIPPV) in prevention of extubation failure in mechanically ventilated preterm neonates weighing less than 2,000 g. METHODS: This randomized controlled trial was conducted in the neonatal intensive care unit of a tertiary care teaching hospital. Preterm neonates weighing less than 2,000 g, mechanically ventilated for more than 24 h were included after extubation. Neonates were randomized into two groups. Group 1 was given unsynchronized nasal intermittent positive pressure ventilation with shortened endotracheal tube by ventilator and Group 2 was given head box oxygen, fraction of oxygen in inspired air was 50%. Primary outcome variable was rate of extubation failure within 72 h of extubation. RESULTS: Birth weight, gestational age, age at intubation, indication for mechanical ventilation and antenatal details were comparable in the two groups. Extubation failure rate was 16% in Group 1 vs, 63% in Group 2 (RR = 0.25; 95% CI: 0.12, 0.51, p value = 0.00), that is a reduction of 47%.Unsynchronized nasal intermittent positive pressure ventilation did not have any serious side effects, however it did not reduce total hospital stay. CONCLUSIONS: Unsynchronized Nasal Intermittent Positive Pressure Ventilation is a simple technique of noninvasive ventilation which significantly reduces the rate of extubation failure in preterm neonates and is not associated with serious side effects. PMID: Patient: Intervention: Comparison: Outcome: preterm neonates (weighing < 2000 g and mechanically ventilated) unsynchronized nasal intermittent positive pressure ventilation (UNIPPV) head box oxygen extubation failure rate was 16% vs. 63%
12 So, results suggest that UNIPPV reduces extubation failure in preterm neonates compared to head box oxygen. How confident are we in this trial s demonstration of that outcome? (Does it meet LOE 1 criteria?) Patient oriented outcome? YES (extubation failure) Not LOE 3! Can be LOE 1 or LOE 2
13 Allocation concealed? YES Blinded? NO (but could it be? In theory, outcome assessors could have been blinded. They weren t but the outcomes being assessed are objective)
14 Adequate Sample size (> 30 / group) Adequate follow-up (> 80%) Intention-to-Treat Analysis? YES YES YES
15 Baseline Differences?
16 DMP Summary o unsynchronized nasal intermittent positive pressure ventilation may reduce need for reintubation in preterm neonates weighing < 2 kg (4.4 lbs) (level 2 [mid-level] evidence) based on randomized trial with baseline differences 90 preterm neonates (mean gestational age 31 weeks) weighing < 2 kg (4.4 lbs) randomized after extubation to unsynchronized nasal intermittent positive pressure ventilation (UNIPPV) vs. oxygen by head box (fraction of oxygen in inspired air 50%) all infants had mechanical ventilation for > 24 hours prior to baseline baseline differences comparing UNIPPV group vs. head box oxygen group mean duration of mechanical ventilation hours vs hours (p = 0.01) positive blood culture in 40% vs. 60% (p = 0.06) comparing UNIPPV vs. head box oxygen need for reintubation within 72 hours in 15.6% vs. 62.2% (p < 0.01, NNT 3) mean hospital stay 16 days vs. 20 days (not significant) UNIPPV associated with increase in nasal trauma and agitation (p = 0.04 for each) Reference - Indian J Pediatr 2011 Jul;78(7):801
17 Your Turn
18 Critical Appraisal of a Randomized Trial Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial Reference - Lancet 2017 Mar 18;389(10074):1103 What conclusion do you draw? How confident are you? Why?
19 Concerns? Discontinuation rates? 22.6% overall Are they different between groups? Were patients who discontinued included in analysis? Only 3 patients lost to follow-up Effect size? Anything else?
20 Results Mean Reduction in PANSS negative symptom scores 8.63 with cariprazine vs with placebo mean difference 1.48 (95% CI ), p = Is this difference clinically important? Cohen's d = ( ) = (small to moderate effect) Response Rate ( 20% reduction in PANSS negative symptom score) 69% vs. 58% (95 % CI for difference 2.3%-19.9%) (p = by raw numbers, simple OR 1.6) (repeated measures OR 2.08, p = )
21 DMP Summary If conclusion is based mostly on the primary outcome: cariprazine monotherapy may improve negative symptoms compared to risperidone monotherapy in adults with stable schizophrenia with predominantly negative symptoms but without depression (level 2 [mid-level] evidence) based on randomized trial with confidence interval including differences that may not be clinically important 461 adults 65 years old (median age 40 years) with stable schizophrenia > 2 years and predominantly negative symptoms (blunted affect, emotional withdrawal, passive or apathetic social withdrawal, lack of spontaneity) > 6 months were randomized to cariprazine vs. risperidone for 26 weeks o cariprazine starting dose 1.5 mg/day orally titrated to target dose 4.5 mg/day over 14 days o (maximum dose 6 mg/day) risperidone starting dose 2 mg/day orally titrated to target dose 4 mg/day over 14 days (maximum dose 6 mg/day) patients excluded for moderate-to-severe depressive symptoms or use of antidepressant within 3 months primary outcome was PANSS negative symptom score (range 7-49 points, with higher score indicating worse symptom severity) mean PANSS negative symptom scores at baseline were 27.7 in cariprazine group and 27.5 in risperidone group 23% discontinued trial medication in each group, and 99% included in analyses comparing cariprazine vs. risperidone at 26 weeks o mean reduction in PANSS negative symptom score 8.63 points vs points (95% CI for difference points), significant but CI includes differences that may not be clinically important o adverse events in 53% vs. 57% (no p value reported) cariprazine also associated with significant improvements in psychosocial functioning on Personal and Social Performance Scale treatment-emergent adverse events included insomnia, headache, akathisia, and anxiety Reference - Lancet 2017 Mar 18;389(10074):1103, editorial can be found in Lancet 2017 Mar 18;389(10074):1077
22 DMP Summary If conclusion is based mostly on the secondary dichotomous outcome: cariprazine monotherapy improves negative symptoms compared to risperidone monotherapy in adults with stable schizophrenia with predominantly negative symptoms but without depression (level 1 [likely reliable] evidence) based on randomized trial 461 adults 65 years old (median age 40 years) with stable schizophrenia > 2 years and predominantly negative symptoms (blunted affect, emotional withdrawal, passive or apathetic social withdrawal, lack of spontaneity) > 6 months were randomized to cariprazine vs. risperidone for 26 weeks o cariprazine starting dose 1.5 mg/day orally titrated to target dose 4.5 mg/day over 14 days o (maximum dose 6 mg/day) risperidone starting dose 2 mg/day orally titrated to target dose 4 mg/day over 14 days (maximum dose 6 mg/day) patients excluded for moderate-to-severe depressive symptoms or use of antidepressant within 3 months primary outcome was PANSS negative symptom score (range 7-49 points, with higher score indicating worse symptom severity) mean PANSS negative symptom scores at baseline were 27.7 in cariprazine group and 27.5 in risperidone group 23% discontinued trial medication in each group, and 99% included in analyses comparing cariprazine vs. risperidone at 26 weeks o 20% improvement in PANSS negative symptom score in 69% vs. 58% (p = , NNT 9) o mean reduction in PANSS negative symptom score 8.63 points vs points (p = ) o adverse events in 53% vs. 57% (no p value reported) cariprazine also associated with o significant improvements in psychosocial functioning on Personal and Social Performance Scale o significantly higher rate of 30% improvement in PANSS negative symptom score in post hoc analysis treatment-emergent adverse events included insomnia, headache, akathisia, and anxiety Reference - Lancet 2017 Mar 18;389(10074):1103, editorial can be found in Lancet 2017 Mar 18;389(10074):1077
23 THANK YOU Fabio Di Bello
ACR OA Guideline Development Process Knee and Hip
ACR OA Guideline Development Process Knee and Hip 1. Literature searching frame work Literature searches were developed based on the scenarios. A comprehensive search strategy was used to guide the process
More informationDeterminants of quality: Factors that lower or increase the quality of evidence
Determinants of quality: Factors that lower or increase the quality of evidence GRADE Workshop CBO, NHG and Dutch Cochrane Centre CBO, April 17th, 2013 Outline The GRADE approach: step by step Factors
More informationWhy is ILCOR moving to GRADE?
1 Why is ILCOR moving to GRADE? Associate Professor Peter Morley Director Medical Education Royal Melbourne Hospital University of Melbourne 10 min 2 3 4 5 6 7 Apart from international consensus Allows
More informationNasal versus oral intubation for mechanical ventilation of newborn infants (Review)
Nasal versus oral intubation for mechanical ventilation of newborn infants (Review) Spence K, Barr P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published
More informationSurveillance report Published: 8 June 2017 nice.org.uk. NICE All rights reserved.
Surveillance report 2017 Antenatal and postnatal mental health: clinical management and service guidance (2014) NICE guideline CG192 Surveillance report Published: 8 June 2017 nice.org.uk NICE 2017. All
More informationThe comparison or control group may be allocated a placebo intervention, an alternative real intervention or no intervention at all.
1. RANDOMISED CONTROLLED TRIALS (Treatment studies) (Relevant JAMA User s Guides, Numbers IIA & B: references (3,4) Introduction: The most valid study design for assessing the effectiveness (both the benefits
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationCritical Appraisal Series
Definition for therapeutic study Terms Definitions Study design section Observational descriptive studies Observational analytical studies Experimental studies Pragmatic trial Cluster trial Researcher
More informationNon Invasive Ventilation In Preterm Infants. Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid
Non Invasive Ventilation In Preterm Infants Manuel Sanchez Luna Hospital General Universitario Gregorio Marañón Complutense University Madrid Summary Noninvasive ventilation begings in the delivery room
More informationGATE CAT Intervention RCT/Cohort Studies
GATE: a Graphic Approach To Evidence based practice updates from previous version in red Critically Appraised Topic (CAT): Applying the 5 steps of Evidence Based Practice Using evidence about interventions
More informationSurveillance report Published: 13 April 2017 nice.org.uk. NICE All rights reserved.
Surveillance report 2017 Antisocial behaviour and conduct disorders in children and young people: recognition and management (2013) NICE guideline CG158 Surveillance report Published: 13 April 2017 nice.org.uk
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationExclusion Criteria 1. Operator or supervisor feels specific intra- procedural laryngoscopy device will be required.
FELLOW Study Data Analysis Plan Direct Laryngoscopy vs Video Laryngoscopy Background Respiratory failure requiring endotracheal intubation occurs in as many as 40% of critically ill patients. Procedural
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationResults. NeuRA Treatments for dual diagnosis August 2016
Introduction Many treatments have been targeted to improving symptom severity for people suffering schizophrenia in combination with substance use problems. Studies of dual diagnosis often investigate
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationControlled Trials. Spyros Kitsiou, PhD
Assessing Risk of Bias in Randomized Controlled Trials Spyros Kitsiou, PhD Assistant Professor Department of Biomedical and Health Information Sciences College of Applied Health Sciences University of
More informationSystematic Reviews. Simon Gates 8 March 2007
Systematic Reviews Simon Gates 8 March 2007 Contents Reviewing of research Why we need reviews Traditional narrative reviews Systematic reviews Components of systematic reviews Conclusions Key reference
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationEBM: Therapy. Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University
EBM: Therapy Thunyarat Anothaisintawee, M.D., Ph.D. Department of Family Medicine, Ramathibodi Hospital, Mahidol University How to appraise therapy literature Are the result valid? What are the result?
More informationFacilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)
Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Data Analysis Plan: Apneic Oxygenation vs. No Apneic Oxygenation Background Critically ill patients
More informationCritical Appraisal. Dave Abbott Senior Medicines Information Pharmacist
Critical Appraisal Dave Abbott Senior Medicines Information Pharmacist Aims Identify key components of clinical trial design and apply these to a critical appraisal of the literature Be able to work out
More informationMethod. NeuRA Paliperidone August 2016
Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation
More informationChecklist for Randomized Controlled Trials. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews
The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews Checklist for Randomized Controlled Trials http://joannabriggs.org/research/critical-appraisal-tools.html www.joannabriggs.org
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationTeaching critical appraisal of randomised controlled trials
Teaching critical appraisal of randomised controlled trials Dr Kamal R. Mahtani BSc PhD MBBS PGDip MRCGP Deputy Director Centre for Evidence Based Medicine University of Oxford November 2014 1 objectives
More informationexposure/intervention
Kathleen A. Kennedy, MD, MPH University of Texas Medical School at Houston Medical School Most clinical research evaluates an association between exposure/intervention outcome. 1 Does the investigator
More informationResults. NeuRA Hypnosis June 2016
Introduction may be experienced as an altered state of consciousness or as a state of relaxation. There is no agreed framework for administering hypnosis, but the procedure often involves induction (such
More informationAssessing risk of bias
Assessing risk of bias Norwegian Research School for Global Health Atle Fretheim Research Director, Norwegian Institute of Public Health Professor II, Uiniversity of Oslo Goal for the day We all have an
More informationEVIDENCE DETECTIVES December 28, 2005 Edward Amores, M.D. Reviewed and edited by P. Wyer, M.D. Part I Question Formulation
EVIDENCE DETECTIVES December 28, 2005 Edward Amores, M.D. Reviewed and edited by P. Wyer, M.D. Part I Question Formulation Clinical Scenario Quite often in the Pediatric ED and at times in the adult ED
More informationPrinciples and Methods of Intervention Research
Principles and Methods of Intervention Research NVVO, February 2, 2009 Jan G.P. Tijssen, Ph.D. Academic Medical Center - University of Amsterdam Introduction Pathophysiologic and pharmacological insight
More informationREHABILITATION OF PATIENTS MANAGED IN ICU
REHABILITATION OF PATIENTS MANAGED IN ICU RECOMMENDATIONS Safety to mobilize / exercise: on the website Recommendation 1 All critically ill patients nursed in ICU should be screened closely before active
More informationEmpirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study
Empirical evidence on sources of bias in randomised controlled trials: methods of and results from the BRANDO study Jonathan Sterne, University of Bristol, UK Acknowledgements: Tony Ades, Bodil Als-Nielsen,
More informationTechnology appraisal guidance Published: 26 January 2011 nice.org.uk/guidance/ta213
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Technology appraisal guidance Published: 26 January 2011 nice.org.uk/guidance/ta213 NICE 2018. All rights reserved. Subject
More informationResults. NeuRA Herbal medicines August 2016
Introduction have been suggested as a potential alternative treatment which may positively contribute to the treatment of schizophrenia. Herbal therapies can include traditional Chinese medicines and Indian
More informationAttention deficit hyperactivity disorder (update)
National Institute for Health and Care Excellence Final Attention deficit hyperactivity disorder (update) [I]Withdrawal from pharmacological treatment and drug holidays NICE guideline NG87 Intervention
More informationPICC or peripheral intravenous catheter?
PICC or peripheral intravenous catheter? B.S. Niël-Weise 1, P.J. van den Broek 2 1 Dutch Infection Prevention Working Party, Leiden, The Netherlands 2 Department of Infectious Diseases, Leiden University
More informationWhat is the Cochrane Collaboration? What is a systematic review?
1 What is the Cochrane Collaboration? What is a systematic review? Archie Cochrane (1909-1988) It is surely a great criticism of our profession that we have not organised a critical summary, by specialty
More informationPFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationNeuRA Sleep disturbance April 2016
Introduction People with schizophrenia may show disturbances in the amount, or the quality of sleep they generally receive. Typically sleep follows a characteristic pattern of four stages, where stage
More informationCONSORT 2010 Statement Annals Internal Medicine, 24 March History of CONSORT. CONSORT-Statement. Ji-Qian Fang. Inadequate reporting damages RCT
CONSORT-Statement Guideline for Reporting Clinical Trial Ji-Qian Fang School of Public Health Sun Yat-Sen University Inadequate reporting damages RCT The whole of medicine depends on the transparent reporting
More informationChecklist for Randomized Controlled Trials. The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews
The Joanna Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews Checklist for Randomized Controlled Trials http://joannabriggs.org/research/critical-appraisal-tools.html www.joannabriggs.org
More informationProblem solving therapy
Introduction People with severe mental illnesses such as schizophrenia may show impairments in problem-solving ability. Remediation interventions such as problem solving skills training can help people
More informationUrate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout
Philippine Journal of Internal Medicine Meta-Analysis Urate Lowering Efficacy of Febuxostat Versus Allopurinol in Hyperuricemic Patients with Gout Erika Bianca S. Villazor-Isidro, M.D.*; John Carlo G.
More information5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA
5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for
More informationEarly Rehabilitation in the ICU: Do We Still Need Chest Physiotherapy?
Early Rehabilitation in the ICU: Do We Still Need Chest Physiotherapy? Michelle Kho, PT, PhD Assistant Professor, School of Rehabilitation Science, McMaster University Adjunct Assistant Professor, Department
More informationEvidence Informed Practice Online Learning Module Glossary
Term Abstract Associations Attrition Bias Background and Significance Baseline Basic Science Bias Blinding Definition An abstract is a summary of a research article. It usually includes the purpose, methods,
More information6.4 Enteral Nutrition (Other): Gastrostomy vs. Nasogastric feeding January 31 st, 2009
6.4 Enteral Nutrition (Other): Gastrostomy vs. Nasogastric feeding January 31 st, 2009 Recommendation: There are insufficient data to make a recommendation on gastrostomy feeding vs. nasogastric feeding
More informationCritical Appraisal of RCT
Critical Appraisal of RCT What is critical appraisal? Definition Process of systematically examining research evidence to assess its reliability (validity/internal validity), results and relevance (external
More informationThe role of Randomized Controlled Trials
The role of Randomized Controlled Trials Dr. Georgia Salanti Lecturer in Epidemiology University of Ioannina School of Medicine Outline Understanding study designs and the role of confounding Observational
More informationCopyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD
GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD ASSISTANT PROFESSOR DEPARTMENT OF CLINICAL EPIDEMIOLOGY AND BIOSTATISTICS, MCMASTER UNIVERSITY Nancy Santesso,
More informationPrevious Study Return to List Next Study
A service of the U.S. National Institutes of Health Trial record 1 of 1 for: 42603ATT3013 Previous Study Return to List Next Study A Study to Evaluate Effectiveness and Safety of Prolonged Release OROS
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationA research report of the therapeutic effects of yoga for health and wellbeing Prepared at ScHARR for the British Wheel of Yoga
A research report of the therapeutic effects of yoga for health and wellbeing Prepared at ScHARR for the British Wheel of Yoga About The British Wheel of Yoga The British Wheel of Yoga The British Wheel
More informationResults. NeuRA Motor dysfunction April 2016
Introduction Subtle deviations in various developmental trajectories during childhood and adolescence may foreshadow the later development of schizophrenia. Studies exploring these deviations (antecedents)
More informationDose: Metoclopramide -0.1 mg/kg (max 10 mg) IV, over 15 minutes
Metoclopramide for Refractory Migraine in the ED Specific Care Question : In the pediatric patient diagnosed with refractory migraine, is metoclopramide an effective treatment? Question Originator: Migraine
More informationCRITICAL APPRAISAL OF MEDICAL LITERATURE. Samuel Iff ISPM Bern
CRITICAL APPRAISAL OF MEDICAL LITERATURE Samuel Iff ISPM Bern siff@ispm.unibe.ch Contents Study designs Asking good questions Pitfalls in clinical studies How to assess validity (RCT) Conclusion Step-by-step
More informationNusinersen Use in Spinal Muscular Atrophy
Nusinersen Use in Spinal Muscular Atrophy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Slide 1 Evidence in Focus Endorsement and
More informationEvidence Summary For the Ghana Essential Medicines Committee
Evidence Summary For the Ghana Essential Medicines Committee Title: Caffeine Citrate for treating apnoea in preterm infants Formulation: 1. Injection: 20 mg/ml (equivalent to 10 mg caffeine base/ml) 2.
More informationLiberation from Mechanical Ventilation in Critically Ill Adults
Liberation from Mechanical Ventilation in Critically Ill Adults 2017 ACCP/ATS Clinical Practice Guidelines Timothy D. Girard, MD, MSCI Clinical Research, Investigation, and Systems Modeling of Acute Illness
More informationNON INVASIVE LIFE SAVERS. Non Invasive Ventilation (NIV)
Table 1. NIV: Mechanisms Of Action Decreases work of breathing Increases functional residual capacity Recruits collapsed alveoli Improves respiratory gas exchange Reverses hypoventilation Maintains upper
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010)
Appendix C Quality appraisal tools (QATs) 1. Draft checklist for judging on quality of animal studies (Van der Worp et al., 2010) 2. NICE Checklist for qualitative studies (2012) 3. The Critical Appraisal
More informationCPAP failure in preterm infants: incidence, predictors and consequences
CPAP failure in preterm infants: incidence, predictors and consequences SUPPLEMENTAL TEXT METHODS Study setting The Royal Hobart Hospital has an 11-bed combined Neonatal and Paediatric Intensive Care Unit
More informationChapter 6 Psychoeducation for depression, anxiety and psychological distress: a meta-analysis
Chapter 6 Psychoeducation for depression, anxiety and psychological distress: a meta-analysis Published: Donker, T., Griffiths, K.M., Cuijpers, P., Christensen, H., 2009. Psychoeducation for depression
More informationCritical Review Form Therapy
Critical Review Form Therapy Does End-tidal Carbon Dioxide Monitoring Detect Respiratory Events Prior to Current Sedation Monitoring Practices, Acad Emerg Med 2006; 13:500-504 Objective: To determine the
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationMeta-analyses: analyses:
Meta-analyses: analyses: how do they help, and when can they not? Lee Hooper Senior Lecturer in research synthesis & nutrition l.hooper@uea.ac.uk 01603 591268 Aims Systematic Reviews Discuss the scientific
More informationObjectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions
Guidelines: Evidence or Expert opinion or???? Objectives Need for guidelines? Prakesh Shah Professor, Department of Pediatrics, Mount Sinai Hospital Institute of Health Policy Management and Evaluation
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationDistraction techniques
Introduction are a form of coping skills enhancement, taught during cognitive behavioural therapy. These techniques are used to distract and draw attention away from the auditory symptoms of schizophrenia,
More informationARCHE Risk of Bias (ROB) Guidelines
Types of Biases and ROB Domains ARCHE Risk of Bias (ROB) Guidelines Bias Selection Bias Performance Bias Detection Bias Attrition Bias Reporting Bias Other Bias ROB Domain Sequence generation Allocation
More informationDatabase of Abstracts of Reviews of Effects (DARE) Produced by the Centre for Reviews and Dissemination Copyright 2017 University of York.
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling Brown
More informationMeta Analysis. David R Urbach MD MSc Outcomes Research Course December 4, 2014
Meta Analysis David R Urbach MD MSc Outcomes Research Course December 4, 2014 Overview Definitions Identifying studies Appraising studies Quantitative synthesis Presentation of results Examining heterogeneity
More informationCLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM
CLINICAL DECISION USING AN ARTICLE ABOUT TREATMENT JOSEFINA S. ISIDRO LAPENA MD, MFM, FPAFP PROFESSOR, UPCM Principles of Decision Making Knowing the patient s true state is often unnecessary Does my patient
More informationChecklist for appraisal of study relevance (child sex offenses)
Appendix 3 Evaluation protocols. [posted as supplied by author] Checklist for appraisal of study relevance (child sex offenses) First author, year, reference number Relevance Yes No Cannot answer Not applicable
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION ARIPIPRAZOLE LONG-ACTING INJECTION (Abilify Maintena Otsuka Pharmaceuticals Co. & Lundbeck Canada Inc.) Indication: Schizophrenia Recommendation: The Canadian Drug Expert Committee
More informationILLUMINATE. Effects of torcetrapib in patients at high risk for coronary events NEJM. 2007; 357:
ILLUMINATE. Effects of torcetrapib in patients at high risk for coronary events NEJM. 2007; 357: 2109-2122. ILLUMINATE The most important trial since 2000? Background Inhibition of cholesteryl ester transfer
More informationProphylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants(review)
Cochrane Database of Systematic Reviews Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants (Review) SubramaniamP,HoJJ,DavisPG Subramaniam
More informationResults. NeuRA Mindfulness and acceptance therapies August 2018
Introduction involve intentional and non-judgmental focus of one's attention on emotions, thoughts and sensations that are occurring in the present moment. The aim is to open awareness to present experiences,
More informationName and title of the investigators responsible for conducting the research: Dr Anna Lavizzari, Dr Mariarosa Colnaghi
Protocol title: Heated, Humidified High-Flow Nasal Cannula vs Nasal CPAP for Respiratory Distress Syndrome of Prematurity. Protocol identifying number: Clinical Trials.gov NCT02570217 Name and title of
More informationFile NDA SE5 046/047, NDA SE5 036/037, NDA SE5 020/021
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: 18 June 2007 FROM: TO: SUBJECT: Mitchell V.
More informationRethinking Arterial Catheters in the ICU. Allan Garland, MD, MA Professor of Medicine & Community Health Sciences University of Manitoba
Rethinking Arterial Catheters in the ICU Allan Garland, MD, MA Professor of Medicine & Community Health Sciences University of Manitoba No Conflicts of Interest Introduction The only appropriate rationale
More informationResults. NeuRA Essential fatty acids August 2016
Introduction Alternative treatments are investigated as a possible replacement for antipsychotic medication, which can be associated with severe side effects. Alternative therapies may have less debilitating
More informationCEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews
CEU screening programme: Overview of common errors & good practice in Cochrane intervention reviews Since September 2013, the CEU has been responsible for pre-publication screening of new intervention
More informationAn evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: placebo-controlled studies Howard F M
An evidence-based medicine approach to the treatment of endometriosis-associated chronic pelvic pain: placebo-controlled studies Howard F M Authors' objectives To assess the efficacy of treatment of endometriosis-associated
More informationSYNOPSIS. ER OROS Paliperidone: Clinical Study Report R SCH-301
SYNOPSIS Protocol No.: R076477-SCH-301 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With an Open-Label Extension Evaluating Extended Release OROS Paliperidone in
More informationResults. NeuRA Worldwide incidence April 2016
Introduction The incidence of schizophrenia refers to how many new cases there are per population in a specified time period. It is different from prevalence, which refers to how many existing cases there
More informationMethods in Research on Research. The Peer Review Process. Why Evidence Based Practices Are Needed?
Methods in Research on Research The Peer Review Process. Why Evidence Based Practices Are Needed? Isabelle Boutron METHODS team Research Centre of Epidemiology Biostatistics Sorbonne Paris Cité Paris Descartes
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationFurther data analysis topics
Further data analysis topics Jonathan Cook Centre for Statistics in Medicine, NDORMS, University of Oxford EQUATOR OUCAGS training course 24th October 2015 Outline Ideal study Further topics Multiplicity
More informationVon Reuss and CPAP, Disclosures CPAP. Noninvasive respiratory therapieswhy bother? Noninvasive respiratory therapies- types
Noninvasive respiratory therapiesby a nose? NEO- The Conference for Neonatology February 21, 2014 Disclosures I have no relevant financial relationships to disclose or conflicts of interest to release.
More informationUse of Sacubitril/Valsartan in Heart Failure
Use of Sacubitril/Valsartan in Heart Failure & the PARADIGM-HF trial Sarah Mackenzie, PharmD student, University of Toronto Presentation Outline Overview of: Entresto PARADIGM-HF trial Critical Appraisal
More informationThe RoB 2.0 tool (individually randomized, cross-over trials)
The RoB 2.0 tool (individually randomized, cross-over trials) Study design Randomized parallel group trial Cluster-randomized trial Randomized cross-over or other matched design Specify which outcome is
More informationSystematic reviews: From evidence to recommendation. Marcel Dijkers, PhD, FACRM Icahn School of Medicine at Mount Sinai
Systematic reviews: From evidence to recommendation Session 2 - June 18, 2014 Going beyond design, going beyond intervention: The American Academy of Neurology (AAN) Clinical Practice Guideline process
More informationSYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER
SYNOPSIS Protocol No.: RIS-USA-63 Psychosis in Alzheimer s disease (PAD) analysis Title of Study: A randomized, double-blind, placebo controlled study of risperidone for treatment of behavioral disturbances
More informationDelirium in Critical Care. Recognition, Management, Research tasters. Dr Valerie Page Watford General Hospital
Delirium in Critical Care. Recognition, Management, Research tasters Dr Valerie Page Watford General Hospital What does it look like? Diagnosing delirium CAM-ICU CAM-ICU Feature 1: Acute onset of mental
More informationSYNOPSIS. Study Coordinator. Study centre(s)
Drug product: Seroquel Drug substance(s): Quetiapine Document No.: 1 Edition No.: 1 Study code: D1449C00005 Date: 02 January 2007 SYNOPSIS A Randomized, Parallel Group, Open Trial Examining the Safety,
More information